Cellomics Technology

Executive Summary

Cellomics Technology, founded in 2019 and headquartered in Cambridge, MA, is a private biotechnology company specializing in innovative gene editing tools. The company focuses on high-throughput gene editing and functional genomics, offering products and services that enable precise and efficient genetic modifications for research and drug discovery. Their proprietary platforms aim to address the growing demand for scalable gene editing solutions, particularly in the cell therapy and precision medicine spaces. By providing unique, high-quality tools, Cellomics positions itself to serve a wide range of academic and industrial customers seeking to accelerate genetic research and therapeutic development. Despite being in an early stage with limited public financial data, the company's niche in high-throughput gene editing aligns with key industry trends toward automation and CRISPR-based technologies.

Upcoming Catalysts (preview)

• Q4 2026Launch of a new high-throughput gene editing platform60% success
• H1 2027Strategic partnership or licensing deal with a major pharmaceutical or cell therapy company35% success
• 2026Series A funding round to scale commercialization50% success